Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

14.00
-0.4400-3.05%
Post-market: 13.95-0.0500-0.36%19:49 EDT
Volume:3.04M
Turnover:42.62M
Market Cap:1.10B
PE:6.90
High:14.52
Open:14.30
Low:13.95
Close:14.44
52wk High:16.91
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:2.23
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.75
PE(LYR):7.49

Loading ...

Analysts Are Bullish on These Technology Stocks: Quantum Computing (QUBT), PagerDuty (PD)

TIPRANKS
·
May 12

Analysts Offer Insights on Technology Companies: PagerDuty (PD) and Infosys (INFY)

TIPRANKS
·
May 12

BRIEF-Pagerduty Appoints John Dilullo As Chief Executive Officer

Reuters
·
May 12

PagerDuty Appoints John DiLullo as CEO

MT Newswires Live
·
May 12

PagerDuty names John DiLullo as new CEO

TIPRANKS
·
May 12

PagerDuty names John DiLullo CEO as Jennifer Tejada becomes executive chair

Reuters
·
May 12

PagerDuty Inc - Expects Q1 Revenue of $118 Mln-$120 Mln and FY2027 Revenue of $488.5 Mln-$496.5 Mln

THOMSON REUTERS
·
May 12

PagerDuty Appoints John Dilullo as Chief Executive Officer

THOMSON REUTERS
·
May 12

Press Release: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Dow Jones
·
May 11

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire
·
May 07

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewswire
·
May 07

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

GlobeNewswire
·
May 07

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

GlobeNewswire
·
May 07

PagerDuty announces annual shareholder meeting

Reuters
·
May 05

California Public Utilities Commission Issues Decision in California Water Service’s 2024 General Rate Case, Infrastructure Improvement Plan

GlobeNewswire
·
May 01

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

GlobeNewswire
·
Apr 30

Incyte Exceeds Q1 Expectations Driven by Strong Demand for Core Cancer Therapies

Deep News
·
Apr 28

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

GlobeNewswire
·
Apr 28

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GlobeNewswire
·
Apr 28

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

GlobeNewswire
·
Apr 27